NPNishmitha Puchakayala

Nishmitha Puchakayala

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Nishmitha Puchakayala has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Pharmacological and non-pharmacological management of sleep disturbances in Alzheimer's disease: A systematic review and meta-analysis

    by Arkansh Sharma, Rishu Raj, Mohammad Orooj Azmi, Nishmitha Puchakayala, Anmol Kaur, Poorvikha S, Vinay Suresh, Abhigyan Datta, Anusha Rai Deka, Suhrud Panchawagh, et al.

    Background: Sleep disturbances affect half of Alzheimer's disease patients, accelerating cognitive decline and increasing caregiver burden. The comparative effectiveness of available interventions remains unclear. Objective: To compare pharmacological and non-pharmacological interventions on sleep outcomes in Alzheimer's disease using network meta-analysis of randomized controlled trials (RCTs). Methods: Following PRISMA and a registered PROSPERO protocol (CRD420250653178), four databases (PubMed/MEDLINE, EMBASE, Scopus, Web of Science) were searched through July 2026 for RCTs. Pairwise and frequentist random-effects network meta-analyses using Hedges’ g were performed for six sleep outcomes: total sleep time (TST), wake after sleep onset (WASO), nocturnal awakenings (NoA), sleep efficiency, daytime sleep, and daytime naps. A Bayesian network meta-analysis served as a sensitivity analysis. Results: Twelve RCTs (N = 936, 32 study arms) were included. Zolpidem and zopiclone reduced sleep fragmentation, with improvements in NoA (SMD −1.09) and WASO (SMD −0.86), although these findings were based on a single short-term trial. Suvorexant increased TST (SMD 0.376) and increased TST (SMD 0.376), while lemborexant 2.5 mg reduced NoA (SMD −0.98), with favorable short-term tolerability. Walking (SMD −0.48), bright light therapy (SMD −0.37), and NITE-AD (SMD −0.52) reduced NoA, while combined light therapy and melatonin reduced daytime sleep (SMD −0.858). Melatonin monotherapy, trazodone, and mirtazapine showed limited or inconsistent effects. Conclusions: Non-pharmacological interventions may be considered before pharmacological treatment. When pharmacotherapy is required, dual orexin receptor antagonists may be useful for selected sleep outcomes, whereas Z-drugs should be used cautiously given their established safety concerns. Larger, longer-duration head-to-head trials using standardized sleep outcomes are needed.